Evolving synergistic combinations of targeted immunotherapies to combat cancer

I Melero, DM Berman, MA Aznar, AJ Korman… - Nature Reviews …, 2015 - nature.com
I Melero, DM Berman, MA Aznar, AJ Korman, JLP Gracia, J Haanen
Nature Reviews Cancer, 2015nature.com
Immunotherapy has now been clinically validated as an effective treatment for many
cancers. There is tremendous potential for synergistic combinations of immunotherapy
agents and for combining immunotherapy agents with conventional cancer treatments.
Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4)
and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future
approaches to immuno-oncology combination therapy. In this Review, we discuss progress …
Abstract
Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.
nature.com